631PNeoadjuvant therapy for esophageal adenocarcinoma: A propensity score-matched comparison of paclitaxel and carboplatin chemoradiotherapy with cisplatin and 5-fluoruracil-based chemo- or chemoradiotherapy.

MLA

Barbour, A. P., et al. “631PNeoadjuvant Therapy for Esophageal Adenocarcinoma: A Propensity Score-Matched Comparison of Paclitaxel and Carboplatin Chemoradiotherapy with Cisplatin and 5-Fluoruracil-Based Chemo- or Chemoradiotherapy.” Annals of Oncology, vol. 29, Oct. 2018, p. N.PAG. EBSCOhost, https://doi.org/10.1093/annonc/mdy282.015.

APA

Barbour, A. P., Brosda, S., Wijnhoven, B., Hootgem, S. van, Lanschot, J. J. B., Barbour, S., Lagarde, S., Krause, L., Pryor, D., & Thomas, J. (2018). 631PNeoadjuvant therapy for esophageal adenocarcinoma: A propensity score-matched comparison of paclitaxel and carboplatin chemoradiotherapy with cisplatin and 5-fluoruracil-based chemo- or chemoradiotherapy. Annals of Oncology, 29, N.PAG. https://doi.org/10.1093/annonc/mdy282.015

Chicago

Barbour, A P, S Brosda, B Wijnhoven, S van Hootgem, J J B Lanschot, S Barbour, S Lagarde, L Krause, D Pryor, and J Thomas. 2018. “631PNeoadjuvant Therapy for Esophageal Adenocarcinoma: A Propensity Score-Matched Comparison of Paclitaxel and Carboplatin Chemoradiotherapy with Cisplatin and 5-Fluoruracil-Based Chemo- or Chemoradiotherapy.” Annals of Oncology 29 (October): N.PAG. doi:10.1093/annonc/mdy282.015.